NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • XYZ.
  • XY.
  • #TrumpTrade
  • Invest ↗
Sign in Subscribe

Tyson Q4 Profit Jumps; Beef Faces $600M Loss, Trump Scrutiny

Tyson Foods (TSN) reported growth in sales and adjusted profit for Fiscal 2025, driven by strong Chicken and Prepared Foods segments, despite major losses in Beef due to severe cattle shortages and rising prices.

Tyson Q4 Profit Jumps; Beef Faces $600M Loss, Trump Scrutiny
Photo by Cristi Caval on Unsplash
Already have an account? Sign in.
11/10/2025 · 8:16 AM
TSN
/ Read more

Feed↓

Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy
11/10/2025 · 10:56 AM

Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy

Eli Lilly partners with MeiraGTx in a $475M deal for a breakthrough gene therapy, AAV-AIPL1, designed to restore vision in children born legally blind.

/ Subscriber only
MannKind Ends Phase 3 ICoN-1 Trial for Nebulized Clofazimine After Futility Review
11/10/2025 · 10:42 AM

MannKind Ends Phase 3 ICoN-1 Trial for Nebulized Clofazimine After Futility Review

MannKind Corporation discontinues its Phase 3 ICoN-1 trial for nebulized clofazimine (MNKD-101) in NTM lung disease after futility analysis shows no efficacy. The company will focus on developing its dry powder version, MNKD-102.

/ Subscriber only
Historic Breakthrough in GIST Treatment: Cogent’s Bezuclastinib Combination Poised to Become New Standard of Care
Featured/ 11/10/2025 · 10:00 AM

Historic Breakthrough in GIST Treatment: Cogent’s Bezuclastinib Combination Poised to Become New Standard of Care

Cogent Biosciences announced "transformative" success with their experimental drug, bezuclastinib, in combination with sunitinib, significantly delaying disease progression in patients battling advanced GIST (a form of stomach cancer).

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe